查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
到 2030 年自闭症谱系治疗市场预测 - 按药物治疗、疾病、年龄组、分销渠道和地区进行的全球分析
市场调查报告书
商品编码
1339996

到 2030 年自闭症谱系治疗市场预测 - 按药物治疗、疾病、年龄组、分销渠道和地区进行的全球分析

Autism Spectrum Disorder Treatment Market Forecasts to 2030 - Global Analysis By Drug Therapy, Disease (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder and Other Diseases), Age Group, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球自闭症谱系治疗市场规模为 21 亿美元，预计到 2030 年将达到 43 亿美元，预测期内年复合成长率为 9.9%。

自闭症谱系障碍（ASD）是一种由大脑变化引起的发育障碍。一些自闭症谱系障碍 (ASD) 患者被认为患有遗传性疾病。其他原因尚不清楚。据科学家称，一个人最典型的发展方式被认为会因多种导致自闭症谱系障碍（ASD）的原因而发生变化。阿斯伯格症候群、自闭症和广泛性发育障碍（PDD）都属于自闭症谱系（ASD）范畴。

据美国医学会（AMA）预测，2020年美国医疗保健支出将增长9.7%，达到4.1万亿美元，即人均12,530美元。

市场动态：

促进因素

  • 全球自闭症谱系障碍人数增加。
  • 自闭症谱系障碍 (ASD) 诊断患病率的上升增加了对有效干预、治疗和支持系统的需求。这刺激了从行为疗法到药物干预等多种治疗方法的研究、创新和投资。随着社会对自闭症谱系障碍(ASD) 的认识越来越深刻，并寻求改善自闭症谱系障碍(ASD) 患者的生活质量，多样化和综合治疗选择的市场正在扩大、发展和专业化，以满足自闭症谱系障碍(ASD) 患者不断变化的需求。定制方法。

抑制因素

  • 治疗和诊断费用高。
  • 治疗、干预、药物和诊断的费用让许多家庭和医疗保健系统望而却步。这种经济负担往往限制了获得综合护理的机会，导致治疗可用性和质量的不平等。因此，必须解决财务障碍，以确保自闭症谱系障碍患者得到及时有效的干预。努力降低成本、扩大保险覆盖范围和推广无障碍支持系统对于克服这一障碍并为自闭症谱系障碍患者取得更好的结果至关重要。

机会

  • 提高对 ASD 的认识和投资。
  • 公众对自闭症谱系障碍 (ASD) 的了解不断增加，对可及且有效的干预措施的需求也随之增加，从而推动了治疗方法的研究和创新。这种认识也推动了治疗、药物和辅助技术的进步，并吸引了公共和私营部门增加投资。扩大的资金池将有助于开发定制的、基于证据的解决方案，以满足自闭症谱系障碍患者的独特需求。这种认可和投资的协同效应为改善自闭症谱系障碍患者的治疗结果和生活质量铺平了道路。

威胁

  • 有关产品核可的严格法规。
  • 治疗、药物和干预措施的复杂而冗长的审批流程减缓了创新治疗的可用性，并阻碍了自闭症谱系障碍患者及时获得治疗。儘管对于患者安全而言是必要的，但由于相关的时间和成本限制，这些法规可能会阻碍该领域的投资和研究。平衡严格的标准与自闭症谱系障碍患者不断变化的需求的紧迫性是必要的，以确保有前景的治疗方法有效地通过法规环境，最大限度地减少延误并最佳化患者的治疗结果。这是至关重要的。

COVID-19 的影响：

  • COVID-19 的爆发对自闭症谱系障碍 (ASD) 治疗市场产生了重大影响。医疗保健服务、治疗课程和学校停课的中断崩坏了自闭症谱系障碍患者通常的支持系统。虽然远端医疗和远程干预受到关注，但面对面治疗面临挑战。供应链中断影响了药品的供应。这场大流行凸显了对有弹性和适应性的治疗方法的需求。随着社会的复苏，以及远端医疗解决方案的进步，人们将重新关注可及且弹性的干预措施以及混合干预措施，以确保为自闭症患者提供持续和有效的支持。这种重点放在可能塑造未来的方法上ASD 治疗。
  • 预计抗精神病药物市场在预测期内将是最大的市场
  • 抗精神病药物在自闭症谱系治疗市场中占据很大份额。儘管抗精神病药物并未被专门批准用于治疗自闭症谱系障碍，但有时会在仿单标示外开具抗精神病药物来控制攻击性、易怒和重复行为等行为症状。然而，由于潜在的副作用和长期有效性的证据有限，人们对其使用存在担忧。正在进行的研究旨在更好地了解自闭症谱系障碍(ASD) 的有效性和安全性，在解决具有挑战性的行为和最大限度地减少与这些药物相关的风险之间取得平衡。我们的目标是为自闭症谱系障碍(ASD) 患者提供更全面、资讯的治疗。
  • 医院药房业务预计在预测期内年复合成长率最高
  • 在预测期内，医院药房在自闭症谱系治疗市场中的年复合成长率最高。提供基本药物、治疗和干预措施。这些药房提供处方药，如抗精神病药、抗抑郁药和其他可满足自闭症谱系障碍患者不同需求的治疗药物。我们还确保适当的药物管理、剂量和给药，并为护理人员和医疗保健专业人员提供指导和支持。医院药房通过优化治疗计划、促进医疗团队之间的协作以及确保 ASD 患者在受控和监督的环境中接受所需的治疗，帮助改善治疗结果和质量。

占比最大的地区

北美占据重要地位，预计在预测期内将占据最大份额。该地区拥有先进的医疗基础设施、研究能力和不断提高的意识，以及成熟的製药行业和研究机构，促进了自闭症谱系障碍治疗的创新。强大的保险覆盖范围和获得医疗保健的机会有助于改善自闭症谱系障碍患者获得治疗的机会。此外，北美医疗专业人员、研究人员和倡导团体之间的合作方法支持制定循证干预措施和量身定制的治疗计划。这些要素使北美成为塑造 ASD 治疗格局的关键参与者，重点是改善治疗结果和患者福祉。

复合年复合成长率最高的地区

亚太地区要素其庞大且多样化的人口、不断提高的意识以及不断发展的医疗基础设施，在自闭症谱系治疗市场中拥有最高的年复合成长率。我成长了。该地区自闭症谱系障碍患者患病率的上升增加了对有效干预措施的需求，并为研究、创新和治疗方法的投资创造了机会。远端医疗和数字平台的使用范围正在扩大，有助于提供远程支持和治疗。

免费定制服务：

订阅此报告的客户将收到以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（注：基于可行性检查）
  • 竞争标杆管理
    • 根据产品系列、地域分布和战略联盟对主要企业进行基准测试

目录

第1章执行摘要

第2章前言

  • 执行摘要
  • 利益相关者
  • 调查范围
  • 调查方法
    • 资料挖掘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球自闭症谱系治疗市场：通过药物治疗

  • 抗精神病药
  • 抗抑郁药
  • 兴奋剂
  • 安眠药
  • 其他药物

第6章全球自闭症谱系治疗市场：按疾病分类

  • 自闭症
  • 阿斯伯格症候群
  • 广泛性发育障碍 (PDD)
  • 其他疾病

第7章全球自闭症谱系治疗市场：按年龄组

  • 孩子
  • 成人

第8章全球自闭症谱系治疗市场：按分销渠道划分

  • 医院药房
  • 药店/零售药房
  • 网上药房

第9章全球自闭症谱系治疗市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第10章进展

  • 合同、伙伴关係、联盟和合资企业
  • 收购和合併
  • 新产品上市
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Curemark, LLC
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Alembic Pharmaceuticals Limited
  • Aurobindo Pharma Ltd.
  • Merck & Co., Inc.
  • Axial Therapeutics Inc.
  • Novartis AG.
  • F. Hoffmann-La Roche Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • PaxMedica
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Q BioMed Inc.
  • Stalicla
  • Teva Pharmaceutical Industries Ltd.
  • Yamo Pharmaceuticals
  • Zynerba Pharmaceuticals, Inc
Product Code: SMRC23703

According to Stratistics MRC, the Global Autism Spectrum Disorder Treatment Market is accounted for $2.1 billion in 2023 and is expected to reach $4.3 billion by 2030 growing at a CAGR of 9.9% during the forecast period. A developmental condition brought on by variations in the brain is known as autism spectrum disorder (ASD). Some individuals with autism spectrum disorder (ASD) have a recognized distinction, like a genetic illness. Additional causes are still unknown. The most typical ways that people develop are thought to be altered by a number of reasons that contribute to autism spectrum disorder (ASD), according to scientists. Asperger's syndrome, autistic disorder, and pervasive developmental disorder (PDD) are all included in the category of autism spectrum disorder (ASD).

According to American Medical Association (AMA), health spending in the U.S. increased by 9.7% in 2020 to $4.1 trillion or $12,530 per capita.

Market Dynamics:

Driver:

  • Global rise in Autism Spectrum Disorder.
  • The rising prevalence of ASD diagnoses has created a growing demand for effective interventions, therapies, and support systems. This has fueled research, innovation, and investment in developing a wide range of treatments, from behavioral therapies to pharmaceutical interventions. As societies become more aware of ASD and seek improved quality of life for affected individuals, the market for diverse and comprehensive treatment options expands, offering opportunities for advancement, specialization, and tailored approaches to cater to the evolving needs of those with ASD.

Restraint:

  • High cost for treatment and diagnosis.
  • The expenses associated with therapies, interventions, medications, and diagnostic procedures can be prohibitive for many families and healthcare systems. This financial burden often limits access to comprehensive care, resulting in inequities in treatment availability and quality. As a consequence, addressing the affordability barrier becomes crucial to ensuring that individuals with ASD receive timely and effective interventions. Efforts to reduce costs, increase insurance coverage, and promote accessible support systems are essential to overcoming this obstacle and ensuring better outcomes for those with ASD.

Opportunity:

  • Rising awareness pertaining ASD and growing number of investments.
  • Greater public understanding of ASD has led to heightened demand for accessible and effective interventions, encouraging research and innovation in treatment methods. This awareness has also attracted increased investment from both the public and private sectors, driving advancements in therapies, medications, and assistive technologies. The expanding pool of funds allows for the development of tailored and evidence-based solutions that address the unique needs of individuals with ASD. This synergy of awareness and investment paves the way for improved treatment outcomes and enhanced quality of life for those affected by ASD.

Threat:

  • Stringent regulations pertaining to product approval.
  • The complex and lengthy approval processes for therapies, medications, and interventions can delay the availability of innovative treatments, hindering timely access for individuals with ASD. These regulations, while necessary for patient safety, can deter investment and research in the field due to the associated time and cost constraints. Balancing rigorous standards with the urgency to address the evolving needs of those with ASD is essential to ensuring that promising treatments can navigate the regulatory landscape efficiently and effectively, minimizing delays and optimizing patient outcomes.

COVID-19 Impact:

  • The COVID-19 pandemic has significantly impacted the Autism Spectrum Disorder (ASD) treatment market. Disruptions in healthcare services, therapy sessions, and school closures have disrupted the usual support systems for individuals with ASD. Telehealth and remote interventions gained prominence, but in-person therapies faced challenges. Supply chain disruptions affected medication availability. The pandemic highlighted the need for resilient and adaptable treatment approaches. As societies recover, a renewed focus on accessible and flexible interventions, along with advancements in telehealth solutions, may shape the future of ASD treatment, emphasizing a blended approach to ensure continuous and effective support for individuals with autism.
  • The antipsychotic drugs segment is expected to be the largest during the forecast period
  • The antipsychotic drugs have a significant share in the Autism Spectrum Disorder Treatment market. While not specifically approved for ASD, they are sometimes prescribed off-label to manage behavioral symptoms such as aggression, irritability, and repetitive behaviors. However, their use raises concern due to potential side effects and limited evidence of long-term benefits. Ongoing research aims to better understand their efficacy and safety in the context of ASD, seeking to strike a balance between addressing challenging behaviors and minimizing the risks associated with these medications, thereby contributing to a more comprehensive and informed treatment landscape for individuals with ASD.
  • The hospital pharmacies segment is expected to have the highest CAGR during the forecast period
  • The hospital pharmacies have the highest CAGR within the Autism Spectrum Disorder Treatment market over the forecast period. Providing access to essential medications, therapies, and interventions. These pharmacies dispense prescribed medications such as antipsychotics, antidepressants, and other therapies that address the diverse needs of individuals with ASD. They ensure proper medication management, dosage, and administration, while also offering guidance and support to caregivers and healthcare professionals. Hospital pharmacies contribute to optimizing treatment plans, facilitating collaboration between medical teams, and ensuring that individuals with ASD receive the necessary treatments within a controlled and supervised environment, thereby contributing to improved outcomes and quality of care.

Region with largest share:

North America holds a significant position and expected to hold a largest share over the forecast period. Due to the advanced healthcare infrastructure, research capabilities, and increasing awareness in the region and the well-established pharmaceutical industry and research institutions drive innovation in ASD interventions. Robust insurance coverage and healthcare accessibility contribute to better treatment access for individuals with ASD. Additionally, North America's collaborative approach among medical professionals, researchers, and advocacy groups supports the development of evidence-based interventions and tailored treatment plans. These factors collectively position North America as a key player in shaping the ASD treatment landscape with a focus on improved outcomes and patient well-being.

Region with highest CAGR:

The Asia Pacific region witnessed highest CAGR in the Autism Spectrum Disorder Treatment market, driven by its large and diverse population, increasing awareness, and growing healthcare infrastructure. The region's rising prevalence of ASD cases has prompted a growing demand for effective interventions, creating opportunities for research, innovation, and investment in treatment approaches. Access to telehealth and digital platforms is expanding, aiding in providing remote support and therapies.

Key players in the market:

Some of the key players in Autism Spectrum Disorder Treatment market include: Curemark, LLC, Eli Lilly and Company, Bristol-Myers Squibb Company, Alembic Pharmaceuticals Limited, Aurobindo Pharma Ltd., Merck & Co., Inc., Axial Therapeutics Inc., Novartis AG., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., PaxMedica, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services Inc., Pfizer Inc., Q BioMed Inc., Stalicla, Teva Pharmaceutical Industries Ltd., Yamo Pharmaceuticals and Zynerba Pharmaceuticals, Inc.

Key Developments:

  • In December2022, Bened Life released the first gut-brain medical probiotic, Neuralli. Made in the United States and utilizing the patented probiotic strain L. plantarum PS128, Neuralli is designed to promote mental health and support neurological conditions including but not limited to Parkinson's disease (PD) and autism spectrum disorder (ASD).
  • In October2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), reported the highly successful completion of the phase 1b trials for its lead drug candidate STP1.
  • In February 2022,Axial Therapeutics announced that the company has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for their lead candidate AB-2004, a molecular therapeutic targeting the gut is being studied for the treatment of irritability associated with ASD.

Drug Therapies Covered:

  • Antipsychotic Drugs
  • Antidepressants
  • Stimulants
  • Sleep Medications
  • Other Drug Therapies

Diseases Covered:

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Other Diseases

Age Groups Covered:

  • Children
  • Adults

Distribution Channels Covered:

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autism Spectrum Disorder Treatment Market, By Drug Therapy

  • 5.1 Introduction
  • 5.2 Antipsychotic Drugs
  • 5.3 Antidepressants
  • 5.4 Stimulants
  • 5.5 Sleep Medications
  • 5.6 Other Drug Therapies

6 Global Autism Spectrum Disorder Treatment Market, By Disease

  • 6.1 Introduction
  • 6.2 Autistic Disorder
  • 6.3 Asperger Syndrome
  • 6.4 Pervasive Developmental Disorder (PDD)
  • 6.5 Other Diseases

7 Global Autism Spectrum Disorder Treatment Market, By Age Group

  • 7.1 Introduction
  • 7.2 Children
  • 7.3 Adults

8 Global Autism Spectrum Disorder Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Drug Stores & Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Autism Spectrum Disorder Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Curemark, LLC
  • 11.2 Eli Lilly and Company
  • 11.3 Bristol-Myers Squibb Company
  • 11.4 Alembic Pharmaceuticals Limited
  • 11.5 Aurobindo Pharma Ltd.
  • 11.6 Merck & Co., Inc.
  • 11.7 Axial Therapeutics Inc.
  • 11.8 Novartis AG.
  • 11.9 F. Hoffmann-La Roche Ltd
  • 11.10 Otsuka Pharmaceutical Co., Ltd.
  • 11.11 PaxMedica
  • 11.12 Janssen Pharmaceuticals, Inc.
  • 11.13 Johnson & Johnson Services Inc.
  • 11.14 Pfizer Inc.
  • 11.15 Q BioMed Inc.
  • 11.16 Stalicla
  • 11.17 Teva Pharmaceutical Industries Ltd.
  • 11.18 Yamo Pharmaceuticals
  • 11.19 Zynerba Pharmaceuticals, Inc

List of Tables

  • Table 1 Global Autism Spectrum Disorder Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 3 Global Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 4 Global Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 5 Global Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 6 Global Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 7 Global Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 8 Global Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 9 Global Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 10 Global Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 11 Global Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 12 Global Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 13 Global Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 14 Global Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 15 Global Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 16 Global Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 17 Global Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 18 Global Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 19 Global Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 20 North America Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 22 North America Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 23 North America Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 24 North America Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 25 North America Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 26 North America Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 27 North America Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 28 North America Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 29 North America Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 30 North America Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 31 North America Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 32 North America Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 33 North America Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 34 North America Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 35 North America Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 36 North America Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 37 North America Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 38 North America Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 39 Europe Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 41 Europe Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 42 Europe Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 43 Europe Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 44 Europe Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 45 Europe Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 46 Europe Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 47 Europe Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 48 Europe Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 49 Europe Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 50 Europe Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 51 Europe Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 52 Europe Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 53 Europe Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 54 Europe Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 55 Europe Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 56 Europe Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 57 Europe Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 58 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 60 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 61 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 62 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 63 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 64 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 65 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 66 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 67 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 68 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 69 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 70 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 71 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 72 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 73 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 74 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 75 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 76 Asia Pacific Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 77 South America Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 79 South America Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 80 South America Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 81 South America Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 82 South America Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 83 South America Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 84 South America Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 85 South America Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 86 South America Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 87 South America Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 88 South America Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 89 South America Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 90 South America Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 91 South America Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 92 South America Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 South America Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 94 South America Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 95 South America Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 96 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Drug Therapy (2021-2030) ($MN)
  • Table 98 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Antipsychotic Drugs (2021-2030) ($MN)
  • Table 99 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 100 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Stimulants (2021-2030) ($MN)
  • Table 101 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Sleep Medications (2021-2030) ($MN)
  • Table 102 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Other Drug Therapies (2021-2030) ($MN)
  • Table 103 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Disease (2021-2030) ($MN)
  • Table 104 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Autistic Disorder (2021-2030) ($MN)
  • Table 105 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Asperger Syndrome (2021-2030) ($MN)
  • Table 106 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Pervasive Developmental Disorder (PDD) (2021-2030) ($MN)
  • Table 107 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Other Diseases (2021-2030) ($MN)
  • Table 108 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 109 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Children (2021-2030) ($MN)
  • Table 110 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Adults (2021-2030) ($MN)
  • Table 111 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 112 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 113 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Drug Stores & Retail Pharmacies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Autism Spectrum Disorder Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)